Capricor Therapeutics Inc. (CAPR) CEO Linda Marban on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/18/20
Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/14/20
Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/20
New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002GlobeNewsWire • 04/29/20
Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell TherapyGlobeNewsWire • 04/03/20
Capricor Therapeutics' (CAPR) CEO Linda Marban on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/19/20
Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products ExpansionGlobeNewsWire • 03/17/20
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 02/13/20
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-MarketGlobeNewsWire • 12/19/19
Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-MarketGlobeNewsWire • 12/17/19
Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/09/19
Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)GlobeNewsWire • 10/21/19
Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 MonthsGlobeNewsWire • 10/07/19
Capricor Therapeutics shares climb 3.6% on news FDA to meet to discuss DMD treatmentMarket Watch • 09/24/19
Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular DystrophyGlobeNewsWire • 09/24/19
Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle SocietyGlobeNewsWire • 09/17/19
Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/06/19
Capricor Therapeutics (CAPR) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/06/19
Will Capricor Therapeutics (CAPR) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 08/01/19